


# UBS (Irl) O'Connor China Long/Short Alpha Strategies UCITS Fund USD Performance **Review**

UBS (Irl) Investor Selection PLC - O'Connor China Long/Short Alpha Strategies UCITS (EUR hedged) Q-PF-acc



**It was another volatile month for the Chinese equity market, with performance in negative territory. All eyes were on the Chinese Communist Party's third plenum, while the continued weakness in macro data continued to weigh heavily on short-term sentiment. Various near-term supportive policies that were announced shortly after the plenum still struggled to bolster the market.**

## Performance (basis EUR, net of fees)<sup>1</sup>



**Past performance is not a reliable indicator of future results.**

## Performance in % (net of fees)<sup>1</sup>

in %	2020	2021	2022	2023	2024 YTD <sup>2</sup>	LTD <sup>3</sup>	2 years	Ø p.a. 2 years
Fund (EUR)	n.a.	n.a.	n.a.	-3.78	12.91	11.23	9.32	4.55

The performance shown does not take account of any commissions, entry or exit charges.

<sup>1</sup> These figures refer to the past. **If the currency of a financial product, financial service or its costs is different from your reference currency, the return and/or costs can increase or decrease as a result of currency fluctuations.** Source for all data and chart (if not indicated otherwise): UBS Asset Management.

<sup>2</sup> YTD: year-to-date (since beginning of the year)

<sup>3</sup> LTD: launch-to-date

## Monthly performance

In July the fund performed negatively with 2.5%. Our state-owned enterprise (SOE) reform and generative AI exposure witnessed an unexpectedly sharp correction, while our net long-tilted exposure was impacted by the global sell-off and volatility. The gains were not enough to cover the losses from long positions.

## YTD performance

YTD as of the end of July, the fund has delivered a positive performance of 12.9%. Our net short exposure to the electric vehicle (EV) supply chain and batteries, net long exposure to generative AI and our SOE reform baskets remain the largest drivers in the year to date.

## Performance contributors

The healthcare sector was a key contributor. The government's continued commitment to revamp the nation's medical system has made it a more functional space for investment based on fundamentals. Another contributor was our net short exposure to the property sector, which remains under pressure in the current economic weakness.

## Performance detractors

Our net long exposure to names within our SOE reform themes was the key detractor this month, following a sell-off that we believe was mainly driven by general profit-taking rather than any changes to fundamentals or long-term policies.

## For more information

UBS Fund Infoline: 0800 899 899

Internet: [www.ubs.com/funds](http://www.ubs.com/funds)

Contact your client advisor

## Portfolio management representatives

John Bradshaw

Mariana Paul

# UBS (Irl) O'Connor China Long/Short Alpha Strategies UCITS Fund USD

## Market Capitalization Exposure (%)<sup>1</sup>

Sector	Long	Short	Net	Gross
Large (greater than USD 10 billion)	56.89	24.20	32.70	81.09
Medium (USD 1 - 10 billion)	17.16	15.79	1.37	32.95
Small (less than USD 1 billion)	6.34	1.07	5.27	7.41
Others	1.37	0.00	1.37	1.37
Total	81.76	41.06	40.71	122.82

<sup>1</sup> Exposure is delta adjusted. 'Others' includes market hedges/indexes.

## Market weights (%)<sup>1</sup>

	Long	Short
China	56.62	32.06
United States	13.75	7.93
Hong Kong	6.91	0.68
Taiwan	3.74	0.30
Other countries	0.75	0.09
Total	81.77	41.06

<sup>1</sup> Exposure is delta adjusted.

## Top 5 long and short positions (%)<sup>1</sup>

	Fund
CHINA RESOURCES POWER HOLDINGS CO LTD	4.30
NVIDIA CORP	4.20
AIA GROUP LTD	4.20
PETROCHINA CO LTD	4.10
CHINA SHENHUA ENERGY CO LTD	4.00
Consumer Discretionary	1.60
Real Estate	1.20
Health Care	1.10
Financials	1.10
Health Care	1.10

<sup>1</sup> Shorts denoted by sector.

## Current investment strategy

As part of our risk management, we de-grossed the portfolio and reduced our net long exposure, although we continue to maintain a constructive view on China. In the near term, we will remain focused on our core high conviction trades such as healthcare, technology and energy, which we believe are rich in alpha opportunities.

## Risks

Counterparty Risk, a significant use of over-the-counter instruments exposes the Fund to potential significant counterparty default risk. The fund may use derivatives, which can reduce or increase investment risk (including the risk of loss due to the bankruptcy of the counterparty). This fund pursues a very active management style. Its performance may therefore deviate considerably from that of a comparable market return. Investments via Shanghai or Shenzhen Stock Connect are subject to additional risks, in particular quota limitations, custody risk, clearing/settlement risk and counterparty risk. Pronounced fluctuations in price are characteristic of emerging economies. Other characteristics include specific risks such as lower market transparency, regulatory hurdles, illiquidity of markets as well as political and social challenges.

Please note that additional fees (e.g. entry or exit fees) may be charged. Please refer to your financial adviser for more details. Investors should read the Key Information Document, Prospectus and any applicable local offering document prior to investing and to get complete information of the risks. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. For a definition of financial terms refer to the glossary available at [www.ubs.com/am-glossary](http://www.ubs.com/am-glossary).

**For marketing and information purposes by UBS.** UBS funds under Irish law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Representative in Switzerland for UBS funds established under foreign law: UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. Paying agent: UBS Switzerland AG, Bahnhofstrasse 45, CH-8001 Zurich. Prospectuses, key information document, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Asset Management Switzerland AG, c/o UBS AG, Bahnhofstrasse 45, 8001 Zürich, Switzerland or from UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. The product described herein aligns to Article 6 Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. Information on sustainability-related aspects pursuant to that regulation can be found on [www.ubs.com/funds](http://www.ubs.com/funds). Before investing in a product please read the latest prospectus and key information document carefully and thoroughly. Any decision to invest should take into account all the characteristics or objectives of the fund as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The calculated performance takes all costs on the fund level into consideration (ongoing costs). The entry and exit costs, which would have a negative impact on the performance, are not taken into consideration. If whole or part of the total costs to be paid is different from your reference currency, the costs may increase or decrease as a result of currency and exchange rate fluctuations. Commissions and costs have a negative impact on the investment and on the expected returns. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency and exchange rate fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. Future performance is subject to taxation which depends on the personal situation of each investor and which may change in the future. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS Asset Management Switzerland AG or a local affiliated company. Source for all data and charts (if not indicated otherwise): UBS Asset Management. This document contains statements that constitute "forward-looking statements", including, but not limited to, statements relating to our future business development. While these forward-looking statements represent our judgments and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. A summary of investor rights in English can be found online at [www.ubs.com/funds](http://www.ubs.com/funds). More explanations of financial terms can be found at [www.ubs.com/am-glossary](http://www.ubs.com/am-glossary).

© UBS 2024. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.